6CM
FOLD

683 Capital Management’s Amicus Therapeutics FOLD Stock Holding History

683 Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-295,500
Closed -$4.19M – 173
2023
Q4 		$4.19M Buy
+295,500
New +$3.36M 0.34% 65

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

683 Capital Management's FOLD Position: Q1 2026 in Review

683 Capital Management reduced its Amicus Therapeutics (FOLD) stake by 3.1% in Q1 2026, selling an estimated $358K and leaving 775,000 shares worth $11.2M. The position accounts for 0.58% of the portfolio, ranked #38.

683 Capital Management first reported a position in FOLD in Q1 2025 and has held it in 5 quarters since. The position peaked at $11.4M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • 683 Capital Management held 775,000 shares of Amicus Therapeutics worth $11.2M as of Q1 2026.
  • 683 Capital Management sold 25,000 Amicus Therapeutics shares in Q1 2026, an estimated $358K.
  • Amicus Therapeutics made up 0.58% of 683 Capital Management's portfolio in Q1 2026, its #38 holding.
  • 683 Capital Management first reported a position in Amicus Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 683 Capital Management's Amicus Therapeutics position peaked at $11.4M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.